Membrane permeabilization of colistin toward pan-drug resistant gram-negative isolates

Brazilian Journal of Microbiology

Volumn 47, Issue 2, 2016, Pages 381-388

  Mohamed, Yasmine Fathy ^a   Abou Shleib, Hamida Moustafa ^a   Khalil, Amal Mohamed ^a   El Guink, Nadia Mohamed ^a   El Nakeeb, Moustafa Ahmed ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Colistin; Leakage; Pan drug resistant; Permeability alteration; Ultrastructure

Indexed keywords

ANTIINFECTIVE AGENT; COLISTIN;

CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; ULTRASTRUCTURE;

ANTI-BACTERIAL AGENTS; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84973160462     PISSN: 15178382     EISSN: 16784405     Source Type: Journal    
DOI: 10.1016/j.bjm.2016.01.007     Document Type: Article

References (35)

1. Sharma R, Sharma CL, Kapoor B. Antibacterial resistance:current problems and possible solutions. Indian J Med Sci.2005;59:120–129.
2. Falagas ME, Bliziotis IA, Kasiakou SK, et al. Outcome ofinfections due to pandrug-resistant (PDR) Gram-negativebacteria. BMC Infect Dis. 2005;5:24.
3. Wang CY, Jerng JS, Chen KY, et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clin Microbiol Infect.2006;12:63–68.
4. Marais E, de Jong G, Ferraz V, Maloba B, Duse AG. Interhospital transfer of pan-resistant Acinetobacter strainsin Johannesburg, South Africa. Am J Infect Control.2004;32:278–281.
5. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) andpandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006;55(Pt12):1619–1629.
6. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emergingantibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589–601.
7. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxinsfor the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333–1341.
8. Nord NM, Hoeprich PD. Polymyxin B and colistin: a criticalcomparison. N Engl J Med. 1964;270:1030–1035.
9. Yow EM, Tan E, Shane L, Schonfeld S, Abu-Nassar H. Colistin(coly-mycin) in resistant bacterial infections. A clinical appraisal. Arch Intern Med. 1961;108:664–670.
10. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2005;25:11–25.
11. Stein A, Raoult D. Colistin: an antimicrobial for the 21stcentury? Clin Infect Dis. 2002;35:901–902.
12. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res. 2006;4:138–146.
13. Landman D, Georgescu C, Martin DA, Quale J. Polymyxinsrevisited. Clin Microbiol Rev. 2008;21:449–465.
14. Hancock RE. Peptide antibiotics. Lancet. 1997;349:418–422.
15. Hermsen ED, Sullivan CJ, Rotschafer JC. Polymyxins:pharmacology, pharmacokinetics, pharmaco dynamics, and clinical applications. Infect Dis Clin North Am. 2003;17:545–562.
16. Glukhov E, Stark M, Burrows LL, Deber CM. Basis forselectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J Biol Chem.2005;280:33960–33967.
17. Finegold SM, Baron EJ. Bailey and Scott’s DiagnosticMicrobiology. St. Louis: The C. V. Mosby Company;1986:70–125, 173–201, 355–387, 397–437, 859–914.
18. Collee JG, Miles RS. Tests for identification of bacteria. In:Collee JG, Duguid JP, Fraser AG, Marmion BP, eds. Mackie andMcCartney, Practical Medical Microbiology. New York: ChurchillLivingstone; 1989:141–160.
19. Howard DH. The preservation of bacteria by freezing inglycerol broth. J Bacteriol. 1956;71:625.
20. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method.Am J Clin Pathol. 1966;45:493–496.
21. Andrews JM. BSAC standardized disc susceptibility testingmethod (version 5). J Antimicrob Chemother. 2006;58:511–529.
22. Andrews JM. Determination of minimum inhibitoryconcentrations. J Antimicrob Chemother. 2001;48(suppl 1):5–16.
23. Barry AL, Craig WA, Nadler H, et al. Methods for DeterminingBactericidal Activity of Antimicrobial Agents; ApprovedGuideline. In: NCCLS document M26-A. PA, USA: NCCLS; 1999.
24. Carson CF, Mee BJ, Riley TV. Mechanism of action of Melaleucaalternifolia (tea tree) oil on Staphylococcus aureus determinedby time-kill, lysis, leakage, and salt tolerance assays and electron microscopy. Antimicrob Agents Chemother.2002;46:1914–1920.
25. Cirioni O, Ghiselli R, Silvestri C, et al. Efficacy of tachyplesinIII, colistin, and imipenem against a multi resistant Pseudomonas aeruginosa strain. Antimicrob Agents Chemother.2007;51:2005–2010.
26. Kim Y, Farrah S, Baney RH. Membrane damage of bacteria bysilanols treatment. Electron J Biotechnol. 2007;10:252–259.
27. Suganuma A. Further studies on the plasma membrane of Staphylococcus aureus. J Cell Biol. 1966;30:208–210.
28. Szoka FJR, Papahadjopoulos D. Procedure for preparation ofliposomes with large internal aqueous space and highcapture by reverse-phase evaporation. Proc Natl Acad Sci U SA. 1978;75:4194–4198.
29. Gupta S, Govil D, Kakar PN, et al. Colistin and polymyxin B: are-emergence. Indian J Crit Care Med. 2009;13:49–53.
30. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitropharmacodynamic properties of colistin and colistinmethanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob AgentsChemother. 2001;45:781–785.
31. Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistinin multidrug-resistant Acinetobacter baumannii. AntimicrobAgents Chemother. 2006;50:2946–2950.
32. Dixon RA, Chopra I. Leakage of periplasmic proteins from Escherichia coli mediated by polymyxin B nonapeptide.Antimicrob Agents Chemother. 1986;29:781–788.
33. Zasloff M. Antimicrobial peptides of multicellular organisms.Nature. 2002;415:389–395.
34. Kitano K, Tomasz A. Triggering of autolytic cell wall degradation in Escherichia coli by beta-lactam antibiotics.Antimicrob Agents Chemother. 1979;16:838–848.
35. Hocquet D, Berthelot P, Roussel-Delvallez M, et al.Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause blood stream infections. Antimicrob Agents Chemother. 2007;51:3531–3536.